Bernstein's Anderson expects 'long, slow' exit from woes at AstraZeneca; Reviva raises $12M;

 @FierceBiotech: Cerulean Pharma's lead nanodrug crashes in lung cancer study. News | Follow @FierceBiotech

@JohnCFierce: No decision yet, but Soriot at AstraZeneca certainly sounds like he's going to do a biosimilars move. More | Follow @JohnCFierce

@RyanMFierce: No surprises here. BG-12 gets nod from EMA committee as first-line MS therapy. Release | Follow @RyanMFierce

> Altas Venture Managing Partner Bruce Booth blogs about upbeat biotech deals trends by the numbers. Item

> With assets from Belgian biotech Galapagos, Cambridge, MA-based DART Therapeutics aims to develop new treatments for Duchenne muscular dystrophy. Release

> Reviva Pharmaceuticals, a West Coast biotech with an interest on schizophrenia, has found $12 million from investors. Article

> Merck's ($MRK) financial chief Peter Kellogg talks about keeping an eye on budget for one of the world's biggest R&D spenders. More

Pharma News

@FiercePharma: Vietnam drug spending makes it a prime pharma target. Article | Follow @FiercePharma

@EricPFierce: Inspection report details why Hospira's hopes were recently dashed by the FDA. Story | Follow @EricPFierce

> EMA recommendation gives Sanofi's MS drug Aubagio another boost. More

> J&J fights $327M Risperdal verdict, saying no one was harmed. Story

Medical Device News

 @FierceMedDev: If you missed our special report yesterday: Med Tech's 2012 R&D big spenders. More | Follow @FierceMedDev

 @MarkHFierce: Big win for GE--expanded FDA approval for an imaging agent, now to gauge risk of death in heart failure patients. Release | Follow @MarkHFierce

 @DamianFierce: Feds: The worry about device tax/regulatory slowdown for mobile apps is mostly hot air. More | Follow @DamianFierce

> 'Symbolic' device tax repeal vote passes in U.S. Senate. More

> Swiss team envisions cheap, durable Dx imaging for Africa. Article

> Study: Asuragen's molecular Dx better at Fragile X detection. Story

And Finally… Top pharma industry analyst Tim Anderson of Bernstein predicts a "long, slow crawl" out from under numerous problems at AstraZeneca ($AZN) after company CEO Pascal Soriot's big reorganization announced this week. Item

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.